Rohto PharmaceuticalLtd Crecimiento futuro
Future controles de criterios 3/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Rohto PharmaceuticalLtd de 13.4% y 9.3% por año respectivamente. Se prevé que el BPA crezca en un 13.4% al año. Se espera que la rentabilidad financiera sea de 12.6% en 3 años.
Información clave
13.4%
Tasa de crecimiento de los beneficios
13.4%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Personal Products | 19.6% |
| Tasa de crecimiento de los ingresos | 9.3% |
| Rentabilidad financiera futura | 12.6% |
| Cobertura de analistas | Good |
| Última actualización | 22 Nov 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Rohto Pharmaceutical Co.,Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Nov 15
Rohto Pharmaceutical Co.,Ltd. Just Missed EPS By 6.8%: Here's What Analysts Think Will Happen Next
Aug 11Recent updates
Rohto Pharmaceutical Co.,Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Nov 15Rohto Pharmaceutical Co.,Ltd. (TSE:4527) Shares Could Be 25% Below Their Intrinsic Value Estimate
Nov 07These 4 Measures Indicate That Rohto PharmaceuticalLtd (TSE:4527) Is Using Debt Reasonably Well
Oct 20Shareholders Should Be Pleased With Rohto Pharmaceutical Co.,Ltd.'s (TSE:4527) Price
Oct 06Returns At Rohto PharmaceuticalLtd (TSE:4527) Appear To Be Weighed Down
Sep 22Here's Why Rohto PharmaceuticalLtd (TSE:4527) Has Caught The Eye Of Investors
Aug 25Rohto Pharmaceutical Co.,Ltd. Just Missed EPS By 6.8%: Here's What Analysts Think Will Happen Next
Aug 11Does Rohto PharmaceuticalLtd (TSE:4527) Have A Healthy Balance Sheet?
Jul 11Calculating The Fair Value Of Rohto Pharmaceutical Co.,Ltd. (TSE:4527)
Jun 23Unpleasant Surprises Could Be In Store For Rohto Pharmaceutical Co.,Ltd.'s (TSE:4527) Shares
Jun 10Rohto PharmaceuticalLtd (TSE:4527) Has More To Do To Multiply In Value Going Forward
May 14These 4 Measures Indicate That Rohto PharmaceuticalLtd (TSE:4527) Is Using Debt Safely
Apr 03Here's Why We Think Rohto PharmaceuticalLtd (TSE:4527) Is Well Worth Watching
Mar 21Rohto PharmaceuticalLtd (TSE:4527) Is Paying Out A Larger Dividend Than Last Year
Mar 07Estimating The Intrinsic Value Of Rohto Pharmaceutical Co.,Ltd. (TSE:4527)
Feb 26Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 3/31/2027 | 382,817 | 40,696 | 34,525 | 49,092 | 9 |
| 3/31/2026 | 357,305 | 36,719 | 31,513 | 42,143 | 9 |
| 3/31/2025 | 317,934 | 32,847 | 25,109 | 39,214 | 9 |
| 9/30/2024 | 282,053 | 27,263 | 29,380 | 39,441 | N/A |
| 6/30/2024 | 278,025 | 30,328 | N/A | N/A | N/A |
| 3/31/2024 | 270,840 | 30,936 | 25,333 | 34,245 | N/A |
| 12/31/2023 | 263,564 | 30,897 | N/A | N/A | N/A |
| 9/30/2023 | 256,220 | 29,779 | 18,967 | 28,610 | N/A |
| 6/30/2023 | 247,580 | 28,473 | N/A | N/A | N/A |
| 3/31/2023 | 238,664 | 26,377 | 21,016 | 30,924 | N/A |
| 12/31/2022 | 231,887 | 25,722 | N/A | N/A | N/A |
| 9/30/2022 | 218,940 | 23,454 | 15,347 | 26,370 | N/A |
| 6/30/2022 | 209,586 | 23,281 | N/A | N/A | N/A |
| 3/31/2022 | 199,646 | 21,018 | 15,922 | 27,250 | N/A |
| 12/31/2021 | 195,698 | 22,593 | N/A | N/A | N/A |
| 9/30/2021 | 189,302 | 21,321 | 13,846 | 25,427 | N/A |
| 6/30/2021 | 184,961 | 19,537 | N/A | N/A | N/A |
| 3/31/2021 | 181,287 | 16,743 | 9,704 | 20,008 | N/A |
| 12/31/2020 | 179,819 | 13,931 | N/A | N/A | N/A |
| 9/30/2020 | 180,903 | 14,283 | 10,794 | 18,162 | N/A |
| 6/30/2020 | 185,058 | 15,130 | N/A | N/A | N/A |
| 3/31/2020 | 188,327 | 15,410 | 12,607 | 19,040 | N/A |
| 12/31/2019 | 187,006 | 11,490 | N/A | N/A | N/A |
| 9/30/2019 | 186,751 | 9,787 | 16,076 | 20,987 | N/A |
| 6/30/2019 | 184,854 | 8,576 | N/A | N/A | N/A |
| 3/31/2019 | 183,582 | 9,799 | 14,828 | 21,745 | N/A |
| 12/31/2018 | 182,328 | 10,058 | N/A | N/A | N/A |
| 9/30/2018 | 180,503 | 10,959 | 14,057 | 21,530 | N/A |
| 6/30/2018 | 176,543 | 10,454 | N/A | N/A | N/A |
| 3/31/2018 | 171,742 | 9,289 | N/A | 19,154 | N/A |
| 12/31/2017 | 167,286 | 11,699 | N/A | N/A | N/A |
| 9/30/2017 | 161,799 | 11,467 | N/A | 15,750 | N/A |
| 6/30/2017 | 157,557 | 10,913 | N/A | N/A | N/A |
| 3/31/2017 | 154,599 | 10,011 | N/A | 13,428 | N/A |
| 12/31/2016 | 158,115 | 9,705 | N/A | N/A | N/A |
| 9/30/2016 | 160,973 | 8,416 | N/A | 9,355 | N/A |
| 6/30/2016 | 164,467 | 9,143 | N/A | N/A | N/A |
| 3/31/2016 | 167,016 | 9,098 | N/A | 11,324 | N/A |
| 12/31/2015 | 164,639 | 10,591 | N/A | N/A | N/A |
| 9/30/2015 | 161,852 | 9,926 | N/A | 14,694 | N/A |
| 6/30/2015 | 157,167 | 9,311 | N/A | N/A | N/A |
| 3/31/2015 | 151,774 | 8,631 | N/A | 11,292 | N/A |
| 12/31/2014 | 148,167 | 6,608 | N/A | N/A | N/A |
| 9/30/2014 | 146,495 | 8,002 | N/A | 12,684 | N/A |
| 6/30/2014 | 143,900 | 7,676 | N/A | N/A | N/A |
| 3/31/2014 | 143,822 | 8,947 | N/A | 18,661 | N/A |
| 12/31/2013 | 139,613 | 9,183 | N/A | N/A | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (13.4% al año) de 4527 es superior a la tasa de ahorro (0.3%).
Beneficios vs. Mercado: Se prevé que los beneficios (13.4% al año) de 4527 crezcan más rápidamente que el mercado JP (7.9% al año).
Beneficios de alto crecimiento: Se prevé que los beneficios de 4527 crezcan, pero no significativamente.
Ingresos vs. Mercado: Se prevé que los ingresos (9.3% al año) de 4527 crezcan más rápidamente que los del mercado JP (4.2% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 9.3% al año) de 4527 crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de 4527 sea baja dentro de 3 años (12.6%).